| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 11, 2022 | ANIK Anika Therapeutics, Inc. | Thompson Jeffery S | Director | Buy | 2,000 | $24.66 | $49,318.00 | +13.2% | -14.2% | +2.0% | |
| Mar 11, 2022 | ANIK Anika Therapeutics, Inc. | Blanchard Cheryl R | President, CEO, Director | Buy | 8,100 | $25.57 | $207,142.82 | +7.5% | -14.2% | +2.0% | |
| Mar 11, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 21,840 | $269.05 | $5,875,986.48 | - | +14.3% | +19.4% | |
| Mar 11, 2022 | VTRS Viatris Inc | Coury Robert J | Executive Chairman | Sell | 500,000 | $10.17 | $5,087,325.00 | -66.7% | +17.2% | +3.1% | |
| Mar 10, 2022 | PCRX Pacira Biosciences, Inc. | Riker Lauren Bullaro76 | Senior Vice President, Finance | Sell | 9,300 | $71.22 | $662,331.00 | -23.0% | -16.8% | -43.9% | |
| Mar 10, 2022 | BCRX Biocryst Pharmaceuticals Inc | Sheridan William P67 | Chief Medical Officer | Sell | 161,139 | $16.88 | $2,719,492.93 | -67.6% | -35.4% | -50.8% | |
| Mar 10, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 184,982 | $266.45 | $49,287,538.82 | - | +18.2% | +19.5% | |
| Mar 10, 2022 | ORGO Organogenesis Holdings Inc. | Montecalvo Antonio S. | Vice President, Health Policy | Sell | 107,436 | $8.40 | $902,688.04 | -47.8% | -36.1% | -72.8% | |
| Mar 9, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 20,018 | $266.52 | $5,335,147.82 | - | +19.2% | +21.7% | |
| Mar 9, 2022 | BUDZ Weed, Inc. | Breen Nicole M | Secretary/ Treasurer | Sell | 15,000 | $0.19 | $2,850.00 | - | - | - | |
| Mar 8, 2022 | BHC Bausch Health Companies Inc. | Gordon Joseph F77 | Pres&Co-head Bausch&Lomb/ Int'l | Sell | 3,889 | $21.76 | $84,624.64 | -4.0% | -57.4% | -60.1% | |
| Mar 8, 2022 | LNTH Lantheus Holdings, Inc. | Niedzwiecki Daniel54 | See Remarks | Sell | 1,762 | $52.08 | $91,761.00 | -1.2% | +37.9% | +48.1% | |
| Mar 8, 2022 | LNTH Lantheus Holdings, Inc. | Sabens Andrea47 | Chief Accounting Officer | Sell | 1,619 | $52.08 | $84,325.27 | -1.2% | +37.9% | +48.1% | |
| Mar 7, 2022 | LNTH Lantheus Holdings, Inc. | Blanchfield Paul54 | Chief Commercial Officer | Sell | 2,228 | $52.55 | $117,076.94 | -2.8% | +35.4% | +39.8% | |
| Mar 7, 2022 | AMPH Amphastar Pharmaceuticals, Inc. | Peters William J52 | CFO, EVP &Treasurer | Sell | 13,026 | $29.35 | $382,313.10 | -10.9% | +21.9% | +14.8% | |
| Mar 7, 2022 | LNTH Lantheus Holdings, Inc. | Marshall Robert J. Jr.53 | CFO And Treasurer | Sell | 4,380 | $52.55 | $230,160.24 | -2.9% | +35.4% | +39.8% | |
| Mar 7, 2022 | BCRX Biocryst Pharmaceuticals Inc | Babu Yarlagadda S66 | Chief Discovery Officer | Sell | 20,000 | $17.16 | $343,200.00 | -8.0% | -40.0% | -50.2% | |
| Mar 7, 2022 | LNTH Lantheus Holdings, Inc. | Walker Carol | Senior Vice President, Quality | Sell | 1,593 | $52.55 | $83,708.96 | -2.0% | +35.4% | +39.8% | |
| Mar 7, 2022 | LNTH Lantheus Holdings, Inc. | Montagut Etienne51 | Chief Business Officer | Sell | 3,115 | $52.55 | $163,687.02 | -3.1% | +35.4% | +39.8% | |
| Mar 7, 2022 | TEVA Teva Pharmaceutical Industries Ltd | Daniell Richard | Exec. VP, European Commercial | Sell | 58,952 | $7.44 | $438,494.04 | -35.6% | +23.6% | +28.8% | |
| Mar 7, 2022 | TEVA Teva Pharmaceutical Industries Ltd | Fridriksdottir Hafrun47 | Executive VP, Global R&D | Sell | 33,579 | $7.45 | $250,219.50 | -9.1% | +23.6% | +28.8% | |
| Mar 7, 2022 | TEVA Teva Pharmaceutical Industries Ltd | Drape Eric51 | Executive VP Global Operations | Sell | 34,792 | $7.44 | $259,018.66 | -14.4% | +23.6% | +28.8% | |
| Mar 7, 2022 | TEVA Teva Pharmaceutical Industries Ltd | Dethlefs Sven | EVP, North America Commercial | Sell | 10,897 | $7.41 | $80,727.01 | -3.4% | +23.6% | +28.8% | |
| Mar 7, 2022 | PRGO Perrigo Co Plc | Janish Ronald Craig61 | EVP, Gbl Ops &Sc &CTO | Sell | 3,954 | $36.73 | $145,232.40 | -20.1% | +9.5% | +6.7% | |
| Mar 7, 2022 | TEVA Teva Pharmaceutical Industries Ltd | Stark David Matthew53 | Exec. VP Chief Legal Officer | Sell | 32,311 | $7.45 | $240,718.26 | -17.4% | +23.6% | +28.8% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.